AstraZeneca on Thursday said it expects its 2021 revenue to grow after its COVID-19 vaccine success topped previous estimates for fourth-quarter sales.
Abzena announced they have been chosen to work with Immunome Inc. to produce IMM-BCP-01 for clinical testing – an investigational therapeutic antibody cocktail for the treatment of COVID-19 being developed to target multiple SARS-CoV-2 antigens.
WuXi STA has agreed to purchase Bristol Myers Squibb’s manufacturing facility in Couvet, Switzerland. The Couvet site will be the first facility in Europe for WuXi STA, a leading Contract Development and Manufacturing Organization. The acquisition will enhance WuXi STA’s existing capabilities while growing capacity to support its partners’ life-saving work.
CatalYm GmbH, a biopharmaceutical company developing novel cancer immunotherapies, announced today the start of clinical development of CTL-002, its proprietary GDF-15 neutralizing antibody designed to enhance effector T cell entry into the tumor microenvironment.
Immunicum AB will move its in-house research and process development activities into a new facility at the Leiden Bio Science Park, the Netherlands. The company said Wednesday it has signed a long-term lease with developer Kadans Science Partner for approximately 1,100 square meters of laboratory and office space in the Plus Ultra Leiden, a new… Continue reading Immunicum AB expanding its Netherlands R&D facilities in Leiden
Myovant Sciences and Pfizer said Monday that the Phase 3 SPIRIT long-term extension study of the investigational once-daily relugolix combination therapy in women with endometriosis reported clinically meaningful reductions in dysmenorrhea (menstrual pain) and non-menstrual pelvic pain over one year (52 weeks) with minimal and stable bone mineral density loss. According to Pfizer’s press release,… Continue reading Promising therapy for menstrual pain tested by Myovant Sciences, Pfizer
LUXEMBOURG–(BUSINESS WIRE)–The increasing diversity of SARS-CoV-2 variants and the potential higher infectivity of some new viral strains, underline the need to identify, trace and track mutations across the complete viral genome. Currently, strains of concern include the B.1.1.7 variant, first identified in the United Kingdom, and the B.1.351 variant, first identified in South Africa. Eurofins… Continue reading Eurofins launches new tests and massive capacity for detecting and monitoring new variants of SARS-CoV-2
Evaxion Biotech, a clinical-stage biotechnology company developing AI-driven immunotherapies, announces today the dosing of the first patient in a Phase I/IIa clinical trial of its adjuvant immunotherapy EVX-02, in combination with checkpoint inhibitors in patients with advanced melanoma.
European Commission’s decision on conditional marketing authorization is expected imminently, after the positive CHMP opinion, which will make BNT162b2 if authorized, the first COVID-19 vaccine available in the European Union.
A phase II clinical trial of a treatment for COVID-19 patients is currently starting at the Medical University of Vienna as a sub-study of the Austrian CoronaVirus Adaptive Clinical Trial (ACOVACT), as an academia-industry collaboration (investigator Initiated trial) between Apogenix AG and its scientific consultant Henning Walczak and his teams at the University of Cologne and University College London (UCL).